Ultragenyx Pharmaceutical Inc. (RARE) Earnings
Ultragenyx Pharmaceutical Inc.'s most recently reported earnings, recent earnings filings (8-K) and headline annual financials, sourced from SEC EDGAR.
Last reported earnings
Nov 3, 2026
From the latest earnings 8-K
Revenue • FY2025
$673M
▲ 20.1%YoY
Diluted EPS • FY2025
-$5.83
▲ 7.3%YoY
Reported earnings dates are based on the latest 8-K (Item 2.02) filings. The next earnings date is an estimate projected from RARE's historical reporting pattern, not a company-confirmed date.
Headline financials
| Period | Revenue | Net income | Gross profit | Dil. EPS | Free cash flow | Op. margin | Rev. growth |
|---|---|---|---|---|---|---|---|
| FY2025 | $673M | -$575M | — | -$5.83 | -$472M | -79.5% | +20.1% |
| FY2024 | $560.23M | -$569.18M | — | -$6.29 | -$421.68M | -95.7% | +29.0% |
| FY2023 | $434.25M | -$606.64M | — | -$8.25 | -$519.07M | -131.1% | +19.5% |
| FY2022 | $363.33M | -$707.42M | — | -$10.12 | -$496.59M | -178.6% | +3.4% |
Recent earnings filings
| Filed | Form | Accession |
|---|---|---|
| Nov 3, 2026 | 8-K (2.02) | 0001193125-26-445342EDGAR |
| Aug 4, 2026 | 8-K (2.02) | 0001193125-26-332802EDGAR |
| May 5, 2026 | 8-K (2.02) | 0001193125-26-206368EDGAR |
| Feb 12, 2026 | 8-K (2.02) | 0001193125-26-048738EDGAR |
| Jan 12, 2026 | 8-K (2.02) | 0001193125-26-009791EDGAR |
| Nov 4, 2025 | 8-K (2.02) | 0001193125-25-264707EDGAR |
| Aug 5, 2025 | 8-K (2.02) | 0000950170-25-103026EDGAR |
| May 6, 2025 | 8-K (2.02) | 0000950170-25-064473EDGAR |
Never miss a RARE filing.
Get an email when RARE files its next 8-K, Form 4, 10-K or 10-Q with the SEC. Free, no account needed.
Free foreverNo account requiredOne-click unsubscribe
Data as of Nov 9, 2026Source: SEC EDGAR.